

# **Carbios**

Results update

# Alternative energy

11 April 2017

Alternext

N/A

# First time profitable

Carbios reported a profit, for the first time in its history, in 2016. First commercial revenues from the Carbiolice JV were the key driver behind the strong results. We have upgraded our forecasts and estimate that the company is funded through 2017 but may require additional financing in 2018. Our valuation range remains unchanged at €2-37 per share.

Year end	Revenue (€m)	PBT* (€m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/15	0.8	(4.0)	(81.3)	0.0	N/A	N/A
12/16	8.9	3.6	131.9	0.0	4.7	N/A
12/17e	1.2	(4.0)	(71.9)	0.0	N/A	N/A
12/18e	2.0	(3.2)	(64.1)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

#### Profits for the first time

Carbios has turned profitable for the first time in its history. It reported 2016 revenues of €8.9m, operating income of €3.5m and net income of €5.0m, all of which are above our expectations. First commercial revenues from the new joint venture, Carbiolice, were the most important element for the positive earnings. Cash management was also strong, with lower than expected cash outflows of €5.0m, and gross cash at the year-end stood at €3.98m. With this and additional grant income of €1m yet to be received in 2017, the company can fully cover cash outflows of c €3m (pre-grant inflows) for the year.

### New revenues, but future financing requirement

We have updated our 2017 forecast and introduce 2018 numbers. Our 2017e EPS loss falls to €0.72 from €0.93 on the back of higher commercial revenues. Carbios's first commercial JV, Carbiolice, which was the most important milestone during 2016, is becoming ever more important as it is now a source of revenues. Besides that, we also include PET recycling revenues from 2017. Nevertheless, as grant funding comes to an end this year, we estimate that cash outflows will exceed available cash of €1.6m as per our forecast for end 2017. We therefore expect the company to require additional financing, eg other grant funding or debt, or to step up commercial revenues beyond our forecast, or a combination of all three.

## Valuation: Unchanged at €23-37 per share

We value Carbios using a DCF methodology with risk-weighted cash flows for its most important processes. This yields a fair value range of €23-37 per share based on different discount rates, with a base case value of €26/share (WACC of 20%). PET, one of the most advanced processes, is the most important component, accounting for 53% of our fair value.

Price Market cap	€6.23 €24m
Net cash (€m) at 31 December 2016	3.8
Shares in issue	3.8m
Free float	11%
Code	ALCRB

#### Share price performance

Primary exchange

Secondary exchange



#### **Business description**

Carbios develops enzyme-based processes for biodegradation and bioproduction of plastics, with a long-term aim of displacing current recycling and production practices.

Next events					
H1 results	September 2017				
Analysts					
Catharina Hillenbrand- Saponar	+44 (0)20 3077 5700				
Roger Johnston	+44 (020 3077 5722				
industrials@edisongroup.com					
Edison profile page					

Carbios is a research client of Edison Investment Research Limited



# FY16 results: Profitability for the first time

In FY16, revenues were €8.9m, operating profit came in at €3.5m and net income at €5.0m. While revenues were slightly short of our estimate of €9.2m, both EBIT and net income were ahead, 12% and 6%, respectively. Remarkably, the company generated first licensing revenues, €8m, from its new joint venture, Carbiolice. Given the short time of just six months since Carbiolice's inception, this shows very strong execution. Other revenues principally consisted of grant funding in line with achieved milestones, namely the conclusion of key stage four and a payment for stage five, the last stage of the project. As expected, costs increased with the scaled-up business. However, the company's EBIT margin was 500bp points above our estimate, reaching 38%. Cash flow was also stronger than expected with €4.5m cash flow from operations, compared to our €3.7m estimate. Total cash outflow, including the investment in Carbiolice, was €5.6m, better than our estimate of €5.4m. With that, the company had cash of €4m (gross) at end December. Its cash burn rate is about €300k per month, which means that cash at hand broadly covers outflows for this year. In addition, the company is still to receive €1m of remaining grant payments for the Thanaplast project for this year before the project completes in 2017.

Exhibit 1: FY16 results							
€000s	FY16a	FY16e	change y-o-y	FY17e			
Revenues	8,870	9,200	999%	1,152			
EBIT	3,538	2,986	N/M	(4,066)			
Net income	4,947	4,661	N/M	(2,698)			
Net cash flow	(5,097)	(5,383)	49.3%	(2,353)			
Cash (gross) at end of period	3,987	3,628	-55.7%	1,634			
Source: Carbios accounts, Edison Investment Research							

### Update to our forecasts

We have updated our FY17 forecasts to reflect the reported numbers. We now include €750k in collaborative revenues from the Carbiolice JV and €300k in upcoming PET recycling partnership revenues, which has just been confirmed by the company (see above), and increase our forecast for R&D tax credits. This increases our revenue forecast to €1.2m. With cost estimates largely unchanged, this now feeds through to an EBIT loss of €4.1m on the basis of total operating expenses of c €5m, and to a net loss of €2.7m. With that, we estimate gross cash at hand of €1.6m at the end of 2017.

Exhibit 2: Forecast changes						
€000s	2017e		2018e			
	Old	New	New			
Revenues	653	1,152	1,950			
EBIT	(4,379)	(4,066)	(3,211)			
Net income	(3,487)	(2,698)	(2,402)			
EPS (€)	(0.93)	(0.72)	(0.64)			
Operating cash flow	(2,658)	(2,399)	(2,288)			
Net cash flow	(3,183)	(2,353)	(3,292)			
Net cash/(debt)	314	1,506	(1,734)			
Source: Carbios accounts, Edison Investment Research						

We also introduce our 2018 forecasts. Our revenue estimate of €2m comprises revenues from Carbiolice, in addition to other commercial PET recycling revenues. As the Thanaplast project will conclude in 2017, there will be no more subsidies revenues. As such, we expect the company to be loss-making as the cost base exceeds revenues. We forecast an EBIT loss of €3.2m and a net loss of €2.4m.

Carbios | 11 April 2017 2



As initial grant and subsidies financing will come to an end this year, and cash flows are still negative, we calculate that Carbios will require further financing in 2018, be it other grants, debt or other sources. We forecast a net cash outflow of €3.3m in FY18, which exceeds estimated cash of €1.6m at end-2017. That said, should the company be able to step up commercial revenues, it might reduce financing requirements.

### Industrial and commercial steps ahead

The company has delivered impressive progress through 2016. Most importantly, it agreed its first joint venture, Carbiolice, in partnership with Limagrain and Bpifrance (see our <u>outlook note</u> of 28 September 2016 and discussion above), and has shown its first positive commercial impact. It has also strengthened its intellectual property: it has been granted two patents in the US, one for enzyme inclusion in plastics and one for PLA degradation. Carbios has also achieved a new patent in China for enzymatic biodegradation of PLA, which underpins its market expansion strategy in agricultural mulching films. Furthermore, it has taken forward its PLA production process by validating its in vivo enzymatic polymerisation process. Lastly, the company has taken a step forward by adapting the polyester biorecycling process for crystalline PET material, which is key for the very important plastic bottle market, one of Carbios's potential future growth markets.

The company now needs to drive further commercial roll-out to grow commercial revenues as Bpifrance/Thanaplast financing will come to an end in 2017 and/or contemplate additional financing from 2018.

Carbios | 11 April 2017 3



ear end 31 December	€000s	2013	2014	2015	2016	2017e	2018e
PROFIT & LOSS		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
Revenue		900	664	837	8,870*	1,152	1,950
Cost of Sales		(3,164)	(2,912)	(3,145)	(2,980)	(2,831)	(2,774)
Gross Profit		(2,264)	(2,248)	(2,308)	5,890	(1,679)	(824)
BITDA		(3,077)	(3,283)	(3,896)	3,761	(3,824)	(2,976)
Operating Profit (before amort. and except.)		(3,116)	(3,364)	(4,062)	3,538	(4,066)	(3,211)
ntangible Amortisation		0,110)	(3,304)	(4,002)	0	0	(3,211)
exceptionals		9	15	(23)	0	0	0
Other		0	0	0	0	0	0
Operating Profit		(3,107)	(3,349)	(4,085)	3,538	(4,066)	(3,211)
let Interest		(0)	(3,349)	78	3,336	(4,000)	(3,211)
Profit Before Tax (norm)		(3,116)	(3,316)	(3,984)	3,626	(4,040)	
· ,		(3,110)		(4,007)	3,626	,	(3,170)
Profit Before Tax (FRS 3)			(3,301)			(4,040)	(3,170)
ax		961	1,091	936	1,321	1,342	768
Profit After Tax (norm)		(2,155)	(2,225)	(3,048)	4,947	(2,698)	(2,402)
Profit After Tax (FRS 3)		(2,146)	(2,210)	(3,071)	4,947	(2,698)	(2,402)
verage Number of Shares Outstanding (m)		3.8	3.8	3.8	3.8	3.8	3.8
PS - normalised fully diluted (c)		(57.8)	(59.3)	(81.3)	131.9	(71.9)	(64.1)
EPS - (IFRS) (c)		(57.2)	(58.9)	(81.9)	131.9	(71.9)	(64.1)
Dividend per share (c)		0.0	0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		N/A	N/A	N/A	N/A	N/A	N/A
ESITDA Margin (%)		N/A	N/A	N/A	42.4	N/A	N/A
Operating Margin (before GW and except.) (%)		N/A	N/A	N/A	39.9	N/A	N/A
		IN/A	IV/A	INA	37.7	IV/A	IW/A
BALANCE SHEET							
ixed Assets		243	1,048	1,665	11,270	11,858	12,668
ntangible Assets		72	130	231	371	601	796
angible Assets		14	740	1,258	1,211	1,569	2,183
nvestments		157	178	176	9,688	9,688	9,688
Current Assets		16,113	12,684	10,377	6,162	3,647	2,043
Stocks		0	20	12	15	16	15
Debtors		1,401	1,402	1,224	1,945	1,782	1,813
Cash		14,598	11,099	9,011	3,987	1,634	0
Other		114	163	130	215	215	215
Current Liabilities		(1,110)	(196)	(337)	(494)	(415)	(366)
Creditors		(1,110)	(196)	(337)	(494)	(415)	(366)
Short term borrowings		0	0	0	0	0	0
ong Term Liabilities		(680)	(474)	(571)	(674)	(624)	(2,281)
ong term borrowings		(457)	(152)	(222)	(178)	(128)	(1,785)
Other long term liabilities		(223)	(322)	(349)	(496)	(496)	(496)
let Assets		14,566	13,062	11,134	16,264	14,466	12,064
CASH FLOW							
Operating Cash Flow		(1,532)	(3,546)	(2,595)	4,515	(2,399)	(2,288)
let Interest			48	78	88	27	, , ,
ax		(0)	0	0	00	0	42 0
Capex Acquisitions/disposals		(187)	(867)	(786)	(329) (9,500)	(830)	(1,045)
· · · · · · · · · · · · · · · · · · ·		12 500	1 171	1 1 1 1 5		0	0
inancing		13,500	1,171	1,145	129	850	0
Dividends		0	(2.104)	(2.150)	(5.007)	(2.252)	(2.202)
let Cash Flow		11,781	(3,194)	(2,158)	(5,097)	(2,353)	(3,292)
Opening net debt/(cash)		(2,360)	(14,141)	(10,947)	(8,789)	(3,809)	(1,506)
IP finance leases initiated		0	0	0	0	0	0
		0	0	0	117	50	51
Other Closing net debt/(cash)		(14,141)	(10,947)	(8,789)	(3,809)	(1,506)	1,734

Source: Carbios accounts, Edison Investment Research. Note: \*FY16 revenues include an €8m non-cash payment treated as licensing revenues as per management guidance; this non-cash payment has been adjusted in the operating cash flow accordingly.

Carbios | 11 April 2017 4



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited [4794244]. www.edisongroup.com

#### DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Carbios and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or compileteness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the line line of the line of publication. The securities described in the line of publication. The securities is seed in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information reflects our sincere opinions. The information that we provide or that is derived from our websile is not intended to be, and should not be construed any such as personalised advice. Also, our websile and the information provided by us should not be construed as a financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. A marketin